This review looked at a very small group of two patients who had Madelung's disease and experienced acute respiratory failure. The patients received non-invasive ventilation using a total face mask to help them breathe better. The team reported that this approach successfully managed the acute respiratory failure in these specific cases. This proactive strategy is described as a potentially life-saving option for this rare condition. However, because the study involved only two people, the results cannot be applied to everyone with this disease. The authors note that while this method worked here, larger studies are required to confirm safety and effectiveness. Readers should understand that this early evidence is limited and does not yet prove that this treatment works for all patients with Madelung's disease or related breathing problems. Further research is necessary before this becomes a standard recommendation for broader use.
NIV with total face mask managed acute respiratory failure in two patients with Madelung's disease and COVID-19 pneumoniaNon-invasive ventilation may help patients with Madelung's disease and respiratory failure
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This case series reports on the use of non-invasive ventilation using a total face mask in a population of patients with Madelung's disease. The sample size was two individuals who presented with acute respiratory failure, COVID-19 pneumonia, or obstructive sleep apnea. The primary outcome of interest was the management of acute respiratory failure, which was successfully managed in both cases. No specific adverse event rates or p-values were reported for the primary outcomes. However, bilateral pneumothoraxes were noted as adverse events in the safety profile. The study setting and follow-up duration were not reported. The authors note that the small sample size and observational nature of the data limit the ability to draw definitive conclusions about efficacy or safety across a wider population. Despite these limitations, the findings suggest that a proactive NIV-first approach is a viable and potentially life-saving strategy for this specific clinical scenario. Clinicians should interpret these results with caution given the lack of a control group and the very limited number of participants.